Inscrivez-vous
Newsroom
Arjo interim report January-September 2021
”Our profitable growth continues in the third quarter with net sales growing over 5% organically and a nearly 35% increase in adjusted EBIT. We have also reached several important milestones in the commercialization of the new SEM Scanner in the quarter, including a contract with one of the largest GPOs in the US,” says Joacim Lindoff, President &...
Arjo announces date of 2021 Q3 report and conference call
Arjo will issue its Q3 report for 2021 on Thursday October 28 at 07:00 CET, followed by a conference call at 08:00 CET, hosted by Joacim Lindoff, President & CEO, and Daniel Fäldt, CFO.
Arjo Receives Innovative Technology Contract from Vizient for the Provizio[® ]SEM Scanner
Arjo has been awarded an Innovative Technology Contract for the Provizio SEM Scanner with Vizient, Inc., the largest member-driven healthcare performance improvement company in the US. The contract further acknowledges the unique qualities of the Provizio SEM Scanner and its role in identification of pressure injury risk, which can help caregivers...
Arjo receives 510(k) clearance from US FDA for WoundExpress
Arjo has received 510(k) clearance from the US Food and Drug Administration (FDA) for WoundExpress, an intermittent pneumatic compression (IPC) solution for accelerating healing of venous leg ulcers. The FDA clearance follows several recent studies showing that WoundExpress can significantly improve lower leg wound management.
Arjo interim report January-June 2021
”We close another strong quarter and grow organically by 4,0%, supported by a solid order intake. We successfully navigate the Covid-19 challenges and see a continued recovery within profitable categories like patient handling, service and DVT. Our profitability continues to improve and we report an adjusted EBITDA-margin exceeding 23% for the...
Research establishes clear health-economic argument for including WoundExpress as standard care in the UK
A newly published research paper by Professor Julian Guest et al. shows that treating hard-to-heal venous leg ulcers with WoundExpress improves both clinical and financial outcomes. In combination with standard care, WoundExpress increased the probability of wound healing by 58% and improved the health-related quality of life for patients – with...
Arjo announces date of 2021 Q2 report and conference call
Arjo will issue its Q2 report for 2021 on Thursday July 15 at 07:00 CET, followed by a conference call at 08:00 CET, hosted by Joacim Lindoff, President & CEO, and Daniel Fäldt, CFO.
Resolutions at Arjo’s Annual General Meeting 27 April 2021
Due to the corona pandemic and to limit the risk for spreading the virus, Arjo AB (publ) held the 2021 Annual General Meeting through electronic connection in accordance with the temporary law applicable during 2021. The shareholders could exercise their voting rights at the Meeting only by participating digitally or by postal voting in advance.
Arjo interim report January-March 2021
“We close a strong first quarter where we continue to successfully navigate the Covid-19 challenges. We grow organically by 4,1%, with a strong profitability development where we report our highest gross margin for a single quarter to date, and our adjusted operating profit increases by 45% in comparable currencies. Our rental business grows by...
Arjo announces date of 2021 Q1 report and conference call
Arjo will issue its Q1 report for 2021 on Tuesday April 27 at 07:00 CET, followed by a conference call at 08:00 CET, hosted by Joacim Lindoff, President & CEO, and Daniel Fäldt, CFO.
Arjo Annual Report 2020 – Mobility drives improved outcomes in healthcare
Today Arjo publishes the Annual Report for 2020. A success factor during the year was that Arjo navigated the short-term challenges in connection with the pandemic while capitalizing on new business opportunities and investing in the future. In 2020, Arjo also presented a new strategy for 2030 as well as a new sustainability framework.
Wounds UK publishes consensus around IPC for treating venous leg ulcers – concluding positive results for WoundExpress™
Treating venous leg ulcers is a significant and costly challenge for healthcare. Now 8 experienced UK clinicians collaborate to form a consensus paper, published by Wounds UK, stating that the use of IPC solutions, in particular Arjo’s WoundExpress, can improve both clinical and financial outcomes.
NOTICE OF ANNUAL GENERAL MEETING IN ARJO AB
The shareholders of Arjo AB (publ), Corporate ID No. 559092-8064, are hereby invited to attend the Annual General Meeting on Tuesday, April 27, 2021 at 15.00.
Arjo publishes year-end report January-December 2020
”We put a very strong quarter and year behind us where we have adapted the business to the current circumstances, and supported healthcare in a challenging period. At the same time, we have exceeded all of the targets that we set at the beginning of the year. The Group grows organically by more than 4% in the fourth quarter with our adjusted...
Arjo announces date of 2020 year-end report and conference call
Arjo will issue its year-end report for 2020 on Wednesday February 3 at 07:00 CET, followed by a conference call at 08:00 CET, hosted by Joacim Lindoff, President & CEO, and Daniel Fäldt, CFO.